CYCC Cyclacel, Inc. Earnings per share for the last twelve months

CYCC (Cyclacel Pharmaceuticals, Inc.) - company brandmark

Cyclacel Pharmaceuticals (CYCC) bases its economics on the creation of closed patent loops via transcription inhibitors. The net income per share over the last 12 months visualizes financial stability, where the value of -304.02 reflects this status. However, geopolitical tension is hindering clinical trials, and an acute liquidity shortage casts doubt on the reliability of FDA regulatory barriers in the face of market risks.

CYCC (Cyclacel Pharmaceuticals) Net earnings per share for the last 12 months history from 07/04/2022 to 09/12/2025

Cyclacel, Inc. - analytical breakdowns and key metrics (CYCC)

- current quotes and average value forecast:
- market capitalization data:
Basic company analysis:cyclacel.com (CYCC)
Mass-produced product of Cyclacel Pharmaceuticals Inc.

Net income per share over 12 months measures the portion of profit attributable to a single common share after all deductions. Investors utilize this metric to assess the real return on capital and protect themselves against overvalued assets. Analyzing the rolling annual net income per share allows for the identification of value accumulation phases. For Cyclacel Pharmaceuticals (CYCC), this metric is secondary, as business success depends on clinical results in cancer treatment. In this instance, the indicator merely reflects the market appetite for high-risk biopharmaceutical assets.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months